Delandistrogene moxeparvovec

Delandistrogene moxeparvovec is indicated for the treatment of ambulatory and non-ambulatory individuals four years of age and older with Duchenne muscular dystrophy with a confirmed mutation in the Duchenne muscular dystrophy gene. Delandistrogene moxeparvovec is designed to deliver into the body a gene that leads to production of Elevidys micro-dystrophin, a shortened protein (138 kDa, compared to the 427 kDa dystrophin protein of normal muscle cells) that contains selected domains of the dystrophin protein present in normal muscle cells. FDA states that the conditional approval is based on detection of successful gene expression; evidence of clinical improvement is still pending. == History ==

The accelerated US Food and Drug Administration (FDA) approval of delandistrogene moxeparvovec was based on data from a randomized clinical trial that established that delandistrogene moxeparvovec increased the expression of the designed micro-dystrophin protein in delandistrogene moxeparvovec-treated individuals aged four to five years with Duchenne muscular dystrophy. == Society and culture ==

Legal status In July 2025, the US Food and Drug Administration (FDA) placed Elevidys on clinical hold; and requested that Sarepta Therapeutics suspend distribution of Elevidys and pause clinical trials on other gene therapy products still in development, following the deaths of three people that had received either Elevidys or an experimental gene therapy using the same viral platform. On 21 July 2025, a few days after the initial announcement, the company placed a voluntary hold on the medication in accordance with the wishes of the FDA. On 28 July 2025, the clinical hold on Elevidys was lifted by the FDA. In July 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended that the drug not be marketed in the European Union. Economics Initial pricing is for a single treatment which is expected to last a lifetime. == References ==